December 09, 2019

What’s A Deal Worth? Benchmarking Pharma Partnering in Europe

Will partnering in Europe be worthwhile for your company?

To help answer this question, we analyzed 43 licensing deals for pharmaceutical products in which Europe was the major territory for a foreign partner between January 2012 and August 2019.

Inside you will find discussion and graphs addressing:

  • Total deal size;
  • Upfront and equity payments;
  • Development, commercial and total milestones;
  • Royalties;
  • Number of products in a deal;
  • Therapeutic area and deal value;
  • Phase of development and deal value;
  • Type of technology;
  • Nationality of licensee;
  • Trends;
  • Conclusions; and
  • Methodology.

Sign-up below to gain access to the full report (PDF):

An extraordinary approach to effective partnering.